<DOC>
	<DOC>NCT02540967</DOC>
	<brief_summary>The objectives of this study are to investigate the safety and effectiveness of Gadovist.</brief_summary>
	<brief_title>Drug Use Investigation of Gadovist.</brief_title>
	<detailed_description>This is a prospective, non-interventional, continuous submission safety study that includes patients who planned Gadolinium (Gd) contrast enhanced Magnetic Resonance Imaging (MRI) in accordance with approved label. The investigator will have made the choice of Gd enhanced MRI (the decision to use Gadovist according the Japanese Package Insert prior to enrolling the patient in this study). The study period is 3 years. Data analysis period is 1 year. In total, 3300 patients will be recruited. For each patient, data are collected as defined in the case report form (CRF) at the visit for MRI examination (as per investigators routine practice).</detailed_description>
	<criteria>Patients who perform contrast enhanced Magnetic Resonance Imaging (MRI) with Gadovist. Patients who are contraindicated based on approved label.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Contrast enhancement in the following MR imaging</keyword>
	<keyword>Brain and spine</keyword>
	<keyword>Body and extremities</keyword>
	<keyword>Gadobutrol</keyword>
</DOC>